Clinical Trials Browser

Withdrawn × daratumumab × Other neoplasm × Clear all

NCT03207542 2018-07-26

Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2 Withdrawn

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic